Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. NASDAQ:SLS (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced preclinical data from studies…
Sellas Life Sciences disclosed preclinical pancreatic cancer data for SLS009, a CDK9 inhibitor, from patient-derived organoid studies. Results are being presented at the AACR Conference on Pancreatic Cancer, running Sept. 25-28, 2026, in San Diego. SLS009 showed stronger single-agent anti-tumor activity than a RAS inhi
SELLAS Life Sciences said it presented preclinical data showing SLS009 activity in pancreatic cancer models at the 2026 AACR Conference on Pancreatic Cancer.